Abstract Whenever adrenal cancer (ACC) is completely removed we should face the dilemma to treat by means of adjuvant therapy or not. In our opinion, adjuvant mitotane is the preferable approach in most cases because the majority of patients following radical removal of an ACC have an elevated risk of recurrence. A better understanding of factors that influence prognosis and response to treatment will help in stratifying patients according to their probability of benefiting from adjuvant mitotane, with the aim of sparing unnecessary toxicity to patients who are likely unresponsive. However, until significant advancements take place, we have to deal with uncertainty using our best clinical judgement and personal experience in the clinical decision process. In the present paper, we present the current evidence on adjuvant mitotane treatment and describe the management strategies of patients with ACC after complete surgical resection. We acknowledge the limit that most recommendations are based on personal experience rather than solid evidence.
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Aim of the review
To present the current evidence on adjuvant mitotane treatment and describe the management strategies of patients with adrenal cancer after complete surgical resection. We acknowledge the limit that most recommendations are based on personal experience rather than solid evidence.
Adjuvant mitotane treatment: what is the evidence?
Adrenal cancer (ACC) is a rare tumor characterized by a poor prognosis since 5-year survival rate after diagnosis is less than 40 % [1] [2] [3] . The main factor influencing prognosis is the possibility of a radical surgery; however, most of the tumors which undergo a complete, margin-free resection will recur, often with distant metastases [4] [5] [6] [7] [8] . This observation has prompted to consider systemic therapy following the removal of ACC; mitotane, a parent compound of the insecticide DDT, has been the drug most frequently employed in an adjuvant setting [1] [2] [3] [5] [6] [7] [8] .
It is known from many years that administration of mitotane was able to destroy the adrenal glands in animal models [9] and to inhibit different enzymatic steps of adrenal steroidogenesis [10] . It is generally thought that mitotane cytotoxicity is mediated through binding of the reactive acyl-chloride to mitochondrial proteins and subsequent oxidative damage through generation of free radicals [10, 11] . It has also been demonstrated that mitotane is able to sensitize H295R and SW-13 ACC cells to ionizing radiations by attenuating DNA repair and interfering with cell proliferation [12] . These findings suggest that mitotane, in addition to the assumed binding to proteins and phospholipids, may interact also with DNA. The activity of mitotane depends on metabolic transformation of the drug in the mitochondria catalyzed by a P-450 enzyme, giving adrenal selectivity [13] .
Mitotane has a narrow therapeutic index and the potential to cause significant toxicity [3, 6, 7] ; thus, it is not an ideal drug to treat patients free of disease. This concept coupled with a limited evidence of efficacy in the literature published since recently [5] [6] [7] [8] [13] [14] [15] [16] [17] made adjunctive treatment with mitotane progressively less appealing. As a matter of fact, no recommendation in favor or against adjuvant treatment was formulated at a consensus conference on ACC held at Ann Arbor in 2003 [18] .
In 2007, we published a retrospective analysis involving a large cohort of patients with ACC, followed at different institutions in Italy and Germany, which challenged this view [19] . In that study, adjuvant mitotane was given to 47 Italian patients after radical surgery, and recurrence-free survival in these patients was compared with that of two independent groups of 55 Italian and 75 German patients whose surgical procedures were not followed by mitotane treatment. Recurrence-free survival (the primary outcome of the study) was significantly prolonged in the mitotane group, while the patients who were left untreated after radical resection of ACC had a significantly higher recurrence rate. Multivariate analysis confirmed that mitotane treatment gave a significant advantage for recurrence-free survival and also overall survival after adjusting for an imbalance of prognostic factors among the different groups [19] . An important finding of the study was that a favorable effect was achieved with low doses (1-5 g per day), a possible explanation for the acceptable adverse event rate [13] . Conversely, severe and disabling toxicity was observed in the previous series employing high doses of mitotane [6] .
Following publication of our study, Bertherat et al. [20] reported that in a cohort of 166 patients, mitotane use following complete tumor removal was not associated with any improvement in disease-free survival. Since mitotane was given to only half of the patients referred to the Authors' institution a selection bias may be anticipated, implying that patients with unfavorable prognostic factors were selected for adjuvant mitotane treatment. This is a major difference with our study, in which the choice to recommend mitotane was made according to a predefined center policy irrespective of patient or tumor characteristics [19] . The predefined treatment assignment and the inclusion of well-matched control groups were considered to be the major advantages of our study as compared with other studies that had less clear treatment assignments and often used historical controls or no controls at all [13] . However, the conclusions of our study, given its retrospective nature, have been heavily criticized [21] . Arguments against adjuvant mitotane are based on the methodological flaws of the available evidence, inherent complexity of mitotane treatment, and lack of factors predicting response to treatment and the toxicity profile of the drug [10] .
More recently, 3 studies addressed the issue of adjuvant mitotane and provided evidence of its efficacy. Although the study from the M.D. Anderson Cancer Center claimed that a state-of-the-art surgical approach may provide a similar survival to surgery plus adjuvant mitotane, the lack of adjuvant mitotane treatment was a factor predicting a higher risk of recurrence [23] . Moreover, a small cohort of patients treated with adjuvant mitotane had a better disease-free survival notwithstanding that they were treated by less experienced surgeons outside the institution; however, adjuvant mitotane did not affect overall survival [22] . Fassnacht and colleagues [23] found that survival was improved in patients with stage II ACC who were managed by a specialized center early after surgery compared to patients who were referred at a later stage, usually after tumor recurrence. Adjuvant mitotane was more frequently used in the first group and treatment was associated with a survival advantage [23] . Wangberg and colleagues [24] reviewing their experience with ACC, showed that an aggressive surgical approach associated with the use of adjuvant mitotane was associated with a satisfactory disease-specific survival. The benefit of mitotane was evident for patients with high-stage ACC and circulating drug levels [14 mg/l [24] .
Controversy on adjuvant mitotane is deemed to continue unless results of prospective, controlled studies become available. We have launched the first randomized trial in an adjuvant setting for ACC, the ADIUVO study, (http:// www.adiuvo-trial.org) under the endorsement of the European Network for the Study of Adrenal Tumours (ENS@T). The study's aim is to assess the efficacy of adjuvant mitotane treatment in prolonging recurrence-free survival in patients with ACC at low-intermediate risk of recurrence. Results of ADIUVO may not be expected before 2017.
Management of adjuvant mitotane treatment
Nowadays, mitotane monitoring is readily available across Europe, where it is provided as a free service by the company distributing mitotane (info@lysodren-europe. com). Mitotane monitoring is a key for an appropriate management of adjuvant treatment giving the possibility to guide dose adjustments and target mitotane concentrations that have been associated with a therapeutic effect. Indeed, plasma mitotane levels [14 mg/l have been found to predict tumor response and improve survival in patients with advanced ACC [15, 16, 25] . Preliminary results of our group demonstrated that the concept of a relationship between plasma concentrations of mitotane and its efficacy is applicable also to disease-free patients who are treated by means of adjuvant therapy [26] .
At San Luigi Hospital, we recommend adjuvant mitotane in the patients perceived to be at high risk of recurrence, while the remainders are encouraged to enter the ADIUVO trial. Although our capability of predicting future risk of ACC recurrence after radical surgery and death is limited, it is generally agreed that stage III-IV ACC, margin-positive resection, and an elevated mitotic index are all factors portending an unfavorable prognosis [27] . Stage IV ACC may be susceptible to complete removal of the primary and metastatic tumor sites, but this condition may be assimilated to a margin-positive resection. Even if solid evidence is lacking, it is usually thought that these patients with stage IV tumors require postoperative medical treatment [28] . An elevated mitotic index is increasingly recognized as a negative prognostic factor and studies showed that cutoff values of 10 % for Ki-67 or 9 mitoses per high-power microscopic field were able to categorize patients at high risk of recurrence [28, 29] .
In our practice, we start adjunctive mitotane treatment as soon as possible after surgery, in any case within 3 months. Although a high-dose regimen is able to provide therapeutic plasma concentrations of mitotane within 1 month in about one third of the patients [30] , we are more cautious with dose escalation (Table 1) . A highdose regimen requires an intensive follow-up and may be more frequently associated with side effects, while our schedule is better tolerated and has less impact on the quality of life. Anyway, we are currently using higher doses than in the past [31] acknowledging the importance of shortening time necessary to reach target mitotane concentrations.
The most common unwanted effects are gastrointestinal manifestations that appear early, independently on mitotane levels. They can be managed with temporary dose reduction, or delay of dose increments, and supportive therapy. Elevated c-glutamyltransferase levels are also frequently observed but are not actually troublesome unless values are exceedingly elevated. Clinically significant liver toxicity is characterized by a marked increase in transaminases and bilirubin, but is infrequently observed in the absence of predisposing conditions [3, 28, [30] [31] [32] . Central neurologic toxicity (cerebellar symptoms, disturbed cognitive performance) is more closely associated with elevated mitotane concentrations ([20 mg/l) but subtler symptoms, such as memory impairment or attention deficit, may be observed in some patients even when they are exposed to lower drug concentrations [15, 16, 32] . A great individual variability in the susceptibility to mitotanerelated unwanted effects is apparent for causes that are still unknown.
Because of the adrenolytic effect of mitotane, all patients should receive glucocorticoid replacement to prevent adrenal insufficiency. Steroid doses are typically higher than in Addison's disease, due to an enhanced metabolic clearance rate of glucocorticoids induced by mitotane [34] . An inadequate treatment of adrenal insufficiency increases mitotane-related toxicity, particularly gastrointestinal side-effects, and reduces tolerance [3, 28, 33] . Mineralocorticoid supplementation is not mandatory in all patients because the zona glomerulosa is partly spared by the toxic effect of mitotane [3, 28, 33] . Moreover, mitotane affects thyroid and gonadal function in a complex way by mechanisms that are still to be completely elucidated. Mitotane administration is associated with low FT4 levels without a compensatory rise in TSH, an effect that becomes apparent early in the course of treatment. This prompts thyroxin replacement, even if the benefit of this measure is difficult to appreciate [28, 32, 33] . In women, gonadal function is usually preserved and most female patients have regular cycles unless PRL levels are significantly increased [28, 32, 33] due to a weak estrogenlike action of mitotane [35] . Conversely, in men mitotane treatment causes sexual dysfunction as a late but common unwanted effect, due to inhibition of testosterone secretion. Sex steroid replacement may become necessary to treat erectile dysfunction in some patients but may worsen gynecomastia (Table 2) [28, 32, 33] .
A general measure to deal with mitotane toxicity is a step down to the previously tolerated dose, or temporary drug withdrawal in the event of severe manifestations. However, well-informed and motivated patients are able to cope with side effects and maintain compliance to treatment. To accomplish this task, it is important to establish a close patient-physician relationship to induce and maintain adherence to treatment. Patients seek advice frequently, also because their local physicians are unfamiliar with mitotane use and its attendant complications, and it is necessary to give a timely counseling to keep patients on treatment.
The optimal duration of therapy remains undefined. Since most ACC recurrences after complete resection occur within 2 years from primary surgery, in our practice we consider such a period as a landmark [28, 33] . However, we are eager to prolong treatment if well tolerated in patients at elevated risk.
Conclusion
Whenever ACC is completely removed we should face the dilemma to treat by means of adjuvant therapy or not. In our opinion, adjuvant mitotane is the preferable approach in most cases, because the majority of patients referred to our institution following adrenalectomy have an elevated risk of recurrent disease.
A better understanding of factors that influence prognosis and response to treatment [36, 37] will help in stratifying patients according to their probability of benefiting from adjuvant mitotane, with the aim of sparing unnecessary toxicity to patients who are likely unresponsive. However, until significant advancements take place, we have to deal with uncertainty using our best clinical judgement and personal experience in the clinical decision process. CBG cortisol-binding globulin, SHBG sex-hormone binding globulin
